Cara Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Operating Revenue	2.81	20.27	41.87	23.03	135.08	Upgrade
Other Revenue	4.33	0.7	-	-	-	Upgrade
Revenue	7.14	20.97	41.87	23.03	135.08	Upgrade
Revenue Growth (YoY)	-65.96%	-49.92%	81.81%	-82.95%	579.28%	Upgrade
Cost of Revenue	36.39	113.55	98.01	81.56	107.07	Upgrade
Gross Profit	-29.25	-92.58	-56.14	-58.54	28.01	Upgrade
Selling, General & Admin	26.53	28.92	31.39	30.55	22.63	Upgrade
Operating Expenses	26.53	28.92	31.39	30.55	22.63	Upgrade
Operating Income	-55.78	-121.5	-87.54	-89.08	5.39	Upgrade
Interest Expense	-8.47	-0.6	-	-	-	Upgrade
Other Non Operating Income (Expenses)	2.29	3.19	2.33	1.39	2.22	Upgrade
EBT Excluding Unusual Items	-61.97	-118.91	-85.21	-87.69	7.6	Upgrade
Merger & Restructuring Charges	-5.57	-	-	-	-	Upgrade
Gain (Loss) on Sale of Investments	0.54	0.4	-0.26	-0.82	0.12	Upgrade
Gain (Loss) on Sale of Assets	-	-	-	0.07	-	Upgrade
Asset Writedown	-4.27	-	-	-	-	Upgrade
Pretax Income	-71.27	-118.51	-85.47	-88.44	7.72	Upgrade
Income Tax Expense	-0.4	-	-	-	-0.69	Upgrade
Net Income	-70.87	-118.51	-85.47	-88.44	8.41	Upgrade
Net Income to Common	-70.87	-118.51	-85.47	-88.44	8.41	Upgrade
Shares Outstanding (Basic)	5	5	4	4	4	Upgrade
Shares Outstanding (Diluted)	5	5	4	4	4	Upgrade
Shares Change (YoY)	1.11%	0.92%	5.79%	5.85%	12.29%	Upgrade
EPS (Basic)	-15.53	-26.26	-19.12	-20.93	2.13	Upgrade
EPS (Diluted)	-15.53	-26.26	-19.12	-20.93	2.13	Upgrade
Free Cash Flow	-61.96	-94.45	-78.77	-60.13	-5.84	Upgrade
Free Cash Flow Per Share	-13.58	-20.93	-17.62	-14.23	-1.46	Upgrade
Gross Margin	-	-	-134.09%	-254.19%	20.74%	Upgrade
Operating Margin	-781.58%	-579.43%	-209.08%	-386.85%	3.99%	Upgrade
Profit Margin	-992.95%	-565.21%	-204.16%	-384.06%	6.23%	Upgrade
Free Cash Flow Margin	-868.19%	-450.46%	-188.15%	-261.10%	-4.32%	Upgrade
EBITDA	-55.59	-121.24	-87.29	-88.84	5.59	Upgrade
EBITDA Margin	-	-	-208.49%	-	4.14%	Upgrade
D&A For EBITDA	0.19	0.26	0.25	0.25	0.21	Upgrade
EBIT	-55.78	-121.5	-87.54	-89.08	5.39	Upgrade
EBIT Margin	-	-	-209.08%	-	3.99%	Upgrade
Revenue as Reported	7.14	20.97	41.87	23.03	135.08	Upgrade

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q